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Summary
Background.— Endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) have
different biological properties, but their potential for synergy in the treatment of injured
myocardium has not been studied extensively.
Aim.— To determine if outcome could be improved by simultaneously transplanting MSCs and
EPCs into a rat model of isoproterenol (ISO)-induced injured myocardium.Cardiac function Methods.— Four weeks after ISO injection, 50 rats were separated randomly into
ﬁve groups (n = 10 per group) and allocated to receive a saline injection (control
group), 200L medium alone, 200L medium plus 2× 106 EPCs, 200L medium plus
2× 106 MSCs, or 200L medium plus a combination of 1× 106 EPCs and 1× 106 MSCs.
Abbreviations: Ang-2, Angiopoietin-2; b-FGF, Basic ﬁbroblast growth factor; BMNC, Bone marrow mononuclear cell; Dil-ac-LDL, Dil-
labelled acetylated low-density lipoprotein; DMSO, Dimethyl sulphoxide; EGM-2, Endothelial cell growth medium-2; ELISA, Enzyme-linked
immunosorbent assay; EPC, Endothelial progenitor cell; FISH, Fluorescence in situ hybridization; FITC-UEA-1, Fluorescein isothiocyanate-
labelled Ulex europaeus agglutinin-1; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; ISO, Isoproterenol; LVEDD, Left ventricular
end-diastolic diameter; LVEDP, Left ventricular end-diastolic pressure; MSC, Mesenchymal stem cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; RT-PCR, Reverse transcriptase polymerase chain reaction; VEGF, Vascular endothelial growth factor;
vWF, von Willebrand factor.
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Echocardiography and invasive catheterization were performed to evaluate dynamic changes
in cardiac performance, 12 weeks after treatment administration.
Results.— Transplanted cells were detected in myocardial tissue by ﬂuorescence in situ
hybridization, indicating either differentiation or integration into cardiac tissue cells. The group
of rats that received both EPCs and MSCs had an increased level of angiogenic growth factors
expression, less collagen deposition, fewer apoptotic cells and an improved regional myocardial
blood ﬂow compared with the other groups; these effects resulted in greater enhancement of
cardiac function in that group.
Conclusion.— Transplantation of EPCs combined with MSCs may represent a novel and efﬁ-
cient therapeutic strategy for enhancing regional myocardial blood ﬂow and improving cardiac
function in injured myocardium.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Les cellules progénitrices endothéliales et cellules souches mésenchymateuses
ont des propriétés différentes, mais ont la faculté d’être synergiques dans le traitement de
l’atteinte myocardique, qui n’a pas été étudié à ce jour de fac¸on exhaustive.
Objectifs.— Déterminer si le suivi pouvait être amélioré par la transplantation simultanée de
cellules endothéliales et de cellules souches mésenchymateuses dans un modèle de rats ayant
une ischémie myocardique induite par l’isoproterenol.
Méthode.— Quatre semaines après l’injection d’isoproterenol, 50 rats ont été séparés de fac¸on
randomisée en cinq groupes (n = 10 par groupe), assignés pour recevoir une injection de sérum
salé (groupe témoin), 200L de médium seulement, 200L de médium avec 2× 106 cellules
endothéliales, 200L de médium plus de 2× 106 cellules souches mésenchymateuses ou 200L
médium plus une combinaison de 106 cellules endothéliales et 106 cellules souches mésenchy-
mateuses. L’échographie et le cathétérisme ont été réalisés pour évaluer des modiﬁcations
hémodynamiques dans la performance myocardique, 12 semaines après l’administration du
traitement.
Résultats.— Les cellules transplantées ont été détectées dans le tissu myocardique par ﬂuores-
cence et hybridation in situ indiquant soit la différenciation ou l’intégration dans les cellules
et les tissus cardiaques. Le groupe de rats ayant rec¸u les cellules endothéliales et les cellules
souches mésenchymateuses avaient une augmentation de l’expression du facteur de croissance
angiogénique, moins de défaut de tissu collagène, moins de cellules apoptotiques et une amélio-
ration de la perfusion myocardique régionale, comparativement aux autres groupes. Ces essais
ont abouti à une amélioration plus importante de la fonction cardiaque dans chacun des groupes.
Conclusion.— La transplantation de cellules endothéliales associées à des cellules souches
mésenchymateuses peut représenter une thérapeutique nouvelle et efﬁcace pour augmenter
le ﬂux myocardique régional et améliorer la fonction cardiaque en cas d’atteinte myocardique.
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ackground
ardiovascular disease is the leading cause of morbidity and
ortality, not only in the Western world, but also in devel-
ping countries, according to a report from the World Health
rganization [1]. With the exception of heart transplanta-
ion, current therapeutic strategies, which aim to enable
he heart to survive and work at a fraction of its original
apacity, have limitations. The regeneration of function-
ng cardiac tissue is a desirable goal in the treatment of
njured myocardium, and the biological properties of stem
ells mean that they may have an important role to play in
his regard [2].
Mesenchymal stem cells (MSCs) have been shown to
nduce myocardial regeneration and improve cardiac func-
ion when injected directly into infarcted myocardium
3]. However, although global left ventricular function had
mproved at four weeks after transplantation, this beneﬁt
a
s
p
brights reserved.
as no longer present at six months after transplantation
4], indicating that the cells were dysfunctional — proba-
ly due to ischaemic conditions. Endothelial progenitor cells
EPCs) have been shown to release angiogenic factors and
ence augment the cardiac performance in an animal model
f acute myocardial infarction [2], probably by improving
egional circulation [2,5]. However, the bone marrow EPCs
re unable to differentiate into cardiomyocytes [6]. Based
n the evidence that MSCs and EPCs have different biological
roperties, we hypothesized that the combined transplan-
ation of MSCs and EPCs into injured myocardium might
vercome these inherent problems and enhance outcome.
Most stem-cell therapy researches have been done in
model of myocardial infarction induced by coronary lig-tion. Isoproterenol (ISO)-induced myocardial injury is a
tandard model for the investigation of pharmacological
rotective effects against ischaemic reperfusion injury [7],
ut is seldom used for stem-cell therapy research; given
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its well-maintained coronary vasculature, we thought that
this model might provide transplanted stem cells with a
better homing environment than the traditional model of
myocardial infarction induced by coronary ligation. There-
fore, using a rat model of ISO-induced myocardial injury, we
aimed to test whether simultaneous transplantation of MSCs
and EPCs could enhance angiogenic signals in patchy areas
of myocardial infarction, improve the survival rate of trans-
planted cells and hence augment the cardiac performance.
Methods
Induction of myocardial injury
Seventy female rats (150—220 g) received ISO 250mg/kg per
day by inguinal subcutaneous injection on two consecutive
days. The second injection was delivered at the opposite
inguinal area to avoid local necrosis by ISO [8]. The rats were
housed in cages under close monitoring for four weeks, then
impaired cardiac function was veriﬁed by echocardiographic
examination. Only rats with a notable decrease (>20% com-
pared with baseline) in ejection fraction were enrolled for
further study.
Isolation and culture of stem cells
Fifty male rats (250—300 g) were used as bone mar-
row mononuclear cell (BMNC) donors. Bone marrow was
collected from the femur and tibia and placed in phosphate-
buffered saline. Samples were separated using Ficoll-Paque
(1.077 g/mL, Huajing, China) density gradient centrifuga-
tion. EPCs were cultured in dishes coated with ﬁbronectin
(10 ug/mL, Sigma, USA). Culture medium (endothelial cell
growth medium-2 [EGM-2], Clonetics, USA) was replaced
twice weekly. The MSC expansion method has been
described previously [9]. Brieﬂy, BMNCs were cultured in
Dulbecco’s modiﬁed Eagle’s medium (Gibco, UAS), sup-
plemented with 10% fetal bovine serum (Gibco, UAS),
L-glutamine (2mmol/L) and penicillin (100U/mL). Non-
adherent cells were removed with each medium change.
Phenotyping of cultured stem cells
By the ninth day, EPCs had replicated rapidly, displaying a
typical ‘cobblestone-like’ appearance (Fig. 1A). Third pas-
sage MSCs had a spindle-shaped morphology (Fig. 1B).
At this stage, cultured EPCs were double stained for
Dil-labelled acetylated low-density lipoprotein (ac-LDL,
10 ug/mL, Biomedical Technologies) and ﬂuorescein isothio-
cyanate (FITC)-labelled Ulex europaeus agglutinin-1 (UEA-1,
1mg/mL, Sigma), at 37 ◦C for 4 and 1 h, respectively. The
cells took up Dil-ac-LDL (shown in red at 570 nm, Fig. 1C) and
were simultaneously stained positive for FITC-UEA-1 (shown
in green at 490 nm, Fig. 1D). Using Photoshop software (ver-
sion 7.0) a merged image was created from Fig. 1C and
D, with double-positive staining shown in yellow (Fig. 1E),
demonstrating typical EPC properties. The numbers of yel-
low and red cells were counted using 10 high-power ﬁelds
of a ﬂuorescent microscope (OLYMPUS IX71-A12FL, Japan).
The purity of the EPCs was calculated as follows: (number
of yellow cells/number of red cells) ×100%.
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The phenotype of the EPC culture was further demon-
trated by immunoﬂuorescence staining, targeting von
illebrand factor (vWF, Biodesign International, USA)
Fig. 1F). More than 83.7% of cultured cells were double
ositive and expressed vWF.
Cultured EPCs and MSCs were analysed by ﬂuorescence-
ctivated cell sorting (FACScan ﬂow cytometer, Becton
ickinson), with isotype-identical antibodies serving as con-
rols. Flow-cytometric analysis showed that on the ninth day
f culture, EPCs expressed CD34 (16.5%, Fig. 1G), CD133
13.9%, Fig. 1H) and vascular endothelial growth factor
eceptor (VEGF; KDR; 57.8%, Fig. 1I), while third passage
SCs were strongly positive for CD90 (90.8%, Fig. 1J), but
egative for CD45 (4.6%, Fig. 1K) and CD34 (0.8%, Fig. 1L).
ptimizing stem-cell ratio
o achieve better proliferative activity, the ﬁrst pas-
age EPCs obtained on the ninth day of culture and the
hird passage MSCs were cultured in serum-free medium
n 96-well culture plates (200L/well) at ratios of 1:2
1× 104 EPCs with 2× 104 MSCs), 1:1 (1.5× 104 EPCs with
.5× 104 MSCs) and 2:1 (2× 104 EPCs with 1× 104 MSCs),
espectively. After 72 h, 10L of 3-(4,5-dimethylthiazol-
-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 g/L) were
dded to each well and the plates were incubated for
nother 4 h. The cell preparation was then mixed with
00L DMSO and shaken for 10min, and optical density was
easured at 570 nm. MTT staining showed that most pro-
iferative activity was achieved when EPCs and MSCs were
ultured at the 1:1 ratio (optical density = 0.65± 0.03 com-
ared with 0.51± 0.05 for the 1:2 ratio and 0.43± 0.05 for
he 2:1 ratio; P < 0.05, respectively). Therefore, on the day
f cell transplantation, ﬁrst passage EPCs obtained on the
inth day were mixed with third passage MSCs at a ratio of
:1 (1× 106 EPCs and 1× 106 MSCs) for delivery.
tem-cell administration
our weeks after injection of ISO, rats with apparent
mpaired cardiac performance (> 20% decrease in ejec-
ion fraction) validated by echocardiography examination
ere randomized into ﬁve groups, and allocated to receive
aline injection (control group), 200L medium alone (EGM-
group), 200L medium plus 2× 106 EPCs (EPC group),
00L medium plus 2× 106 MSCs (MSC group), or 200L
edium plus a combination of 1× 106 EPCs and 1× 106 MSCs
EPC/MSC group).
The rats were intubated (with appropriate anaesthesia),
nd ventilated with room air (60 cycles/min) with a tidal vol-
me of 1mL/kg (DW-2000, Shanghai). The heart was exposed
y a left thoracotomy. Cultured stem cells were injected
venly into the left ventricle wall, and the chest was closed
n layers. The rats were monitored closely for further 12
eeks.
chocardiographic and haemodynamic
valuation
t baseline before ISO injection, four weeks after
SO injection and 12 weeks after cell therapy, two-
imensional echocardiography and M-mode imaging were
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Figure 1. Phenotype of cultured stem cells. On the ninth day, EPCs had a typical ‘cobblestone-like’ appearance (A, × 100). Third passage
MSCs had a spindle-shaped morphology (B, × 200). Dil-ac-LDL (C; in red, × 400) and FITC-UEA-1 (D; in green, × 400) immunostaining was
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WF staining (F, × 100). Flow cytometric analysis showed that some
DR (I). Flow cytometric analysis showed a high ratio of CD90+ cell
arried out at papillary muscle level [10] using an
chocardiographic system with a 14MHz transducer (Acu-
on Sequoia 521, USA). Left ventricular end-diastolic
iameter (LVEDD), ejection fraction and fractional short-
ning ratio were analysed by an independent investi-
ator.
After 12 weeks of observation, all rats underwent inva-
ive catheterization. Brieﬂy, a 1.5 F ﬂuid-ﬁlled catheter
as fully heparinized, introduced through a right carotid
rtery cut-down and inserted into the left ventricle, with
ositioning guided by echocardiography. Left ventricular
ressure tracings were digitized using an analog-to-digital
onverter and stored on computer for analysis. Left ven-
ricular end-diastolic pressure (LVEDP) and maximum rate
f left ventricular pressure rise/fall (±dP/dtmax) were anal-
sed blind, using dedicated software (MPC Systems, 2000M,
hina).
m
t
c
m
bs created (E; in yellow, × 400). EPCs were further phenotyped by
were positive for CD34 (G) and CD133 (H), and that most expressed
but low ratios of CD45+ cells (K) and CD34+ cells (L).
easurement of regional myocardial blood
ow
oloured microspheres were used to evaluate average
egional myocardial blood ﬂow (RMBF). While the ﬂuid-ﬁlled
atheter was still in the left ventricle, it was connected
o a peristaltic pump, and 0.3mL orange coloured micro-
pheres (diameter 15m; Dye-Trak, USA) were injected
irectly into the left ventricle before tissue harvesting.
spiration of a blood sample via the catheter started
everal beats after coloured-microsphere injection, and
ontinued for 1min at a rate of 0.5mL/min. Coloured
icrospheres were recovered and analysed according to
he manufacturer’s instructions. Average RMBF was cal-
ulated as follows: (number of coloured microspheres in
yocardium× 0.5)/(number of coloured microspheres in
lood×weight of myocardium).
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instructions, on tissue slices selected at random. Tissue sec-
tions were examined microscopically at × 400 magniﬁcation
and greater than or equal to 100 cells were counted in 10
ﬁelds (OLYMPUS BH2, Japan). The apoptotic index was cal-
culated as follows: (number of apoptotic cells/total number
of cells)× 100%.
Quantiﬁcation of angiogenic growth factor
protein-expression levels
To assess the level of growth factor secretion, the randomly-
selected heart tissue slices were crushed in ethanoic acid
and centrifuged, and the supernatant was collected. VEGF
(RD, USA), basic ﬁbroblast growth factor (b-FGF, RD, USA)
and angiopoietin-2 (Ang-2, ADL, USA) were measured by
ELISA assay, according to the manufacturer’s instructions.
Quantiﬁcation of Sry gene and angiogenic
growth factor mRNA expression levels
Two-step real time RT-PCR, using SYBR® Green (Molecu-
lar Probes) as a dye, was carried out to analyse levels of
VEGF, b-FGF, Ang-2 and Sry gene mRNA expression. Trizon
(Gibco BRL,CA) was used to isolate mRNA, which was treated
with DNase I and reverse-transcribed with random hex-
amers (Invitrogen), using Moloney murine leukaemia virus.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
from the same tissue lysate was used as an internal control.
The primer pairs for PCR ampliﬁcation, targeting each spe-
ciﬁc gene, were designed using Primer Express 1.5 software
(Applied Biosystems); the sequences are shown in Table 1.
Real time RT-PCR was performed using the ABI 7000 system
(Applied Biosystems, USA) with the following cycle condi-
tions: 45 cycles of 30 s at 95 ◦C for denaturation, 45 s at 59 ◦C
for annealing and 50 s at 72 ◦C for extension. Using ABI Prism
7300 SDS Software, CT methods were used to quantify
the mRNA expression level of each target gene.
Statistical analysis
Numerical values are presented as the mean± standard
deviation (S.D.). Comparisons between the ﬁve groups were
made using a one-way analysis of variance, followed by
the Scheffe-multiple-comparison test. Analyses were per-
formed using SPSS version 10.0 statistical software (SPSS
Table 1 Primer pairs for angiogenic growth factors and
the Sry gene.
Gene Primers
GAPDH F 5′GGCATCCTGACCCTGAAGTA 3′
R 5′GGGGTGTTGAAGGTCTCAAA 3′
rat Sry gene F 5′ GGCTTCAAAGTAGATTAGTTGGG 3′
R 5′ ATGCATTCATGGGGCGCTTGAC 3′
b-FGF F 5′ CGACCCACACGTCAAACTA 3′
R 5′ AGCAGCCGTCCATCTTCCT 3′Combined transplantation of endothelial progenitor cells an
Tissue harvesting
At the end of the 12-week observation period, the rats
were sacriﬁced with an overdose of anaesthetic (ketamine
300mg/kg) and the hearts were harvested. The left ven-
tricle was sliced, perpendicular to the septum, into four
sections, each approximately 4—5mm thick. Because of
the patchiness of the areas of myocardial infarction, and
to avoid sample selection bias, sections were selected
randomly for further analysis, which included immunostain-
ing, RMBF, enzyme-linked immunosorbent assay (ELISA) and
real-time reverse transcriptase-polymerase chain reaction
(RT-PCR). Tissue slices for RMBF and immunostaining were
kept in 4% formalin, and those for ELISA and real-time RT-
PCR were snap frozen and stored at −80 ◦C.
Assessment of engraftment and cell
differentiation
Transplanted male cells in female rat hearts were detected
using ﬂuorescence in situ hybridization (FISH) on parafﬁn-
embedded tissue slices selected at random. A probe speciﬁc
for the rat Y chromosome Sry gene was synthesized (HaoYang
Co, China), with the sequence 5′-ATAGT GTGTA GGTTG
TTGTC CCATT GCAGC-3′. Sections were deparafﬁnized and
denatured at 95 ◦C for 10min, chilled on ice for 5min,
then incubated with the probe at 37 ◦C for 12 h. Nuclei
stained with 5′-FAM-NHS (ﬂavo-green) were detected at
490 nm.
Engrafted Sry-positive cells were phenotyped using
immunoﬂuorescence staining with an antibody against
either cardiac troponin T (monoclonal mouse anti-rat,
Serotec, British) or vWF (rabbit polyclonal, Dako, Den-
mark), further characterizing the transplanted stem cells
on the adjacent slice of FISH tissue section. Phycoerythrin-
conjugated IgG antibody (BD, USA) was used as a secondary
antibody.
Evaluation of myocardial ﬁbrosis
Cardiac muscle ﬁbrosis was detected using Masson’s
trichrome staining of tissue slices selected at random. For
each slice, 10 randomly selected ﬁelds were captured (mag-
niﬁcation× 100) and images were digitized and analysed
with a digital image analyser (MIQAS, Qiuwei Co, China).
Quantiﬁcation of myocardial capillary density
Capillaries in the myocardium were semiquantiﬁed using
immunohistochemical staining of endothelial cells with a
polyclonal rabbit anti-vWF (Dako, Denmark), in tissue slices
selected at random. A capillary vessel was deﬁned as having
a diameter < 20m. The number of capillaries was counted
under a light microscope (magniﬁcation× 250, OLYMPUS
BH2, Japan) for 10 random ﬁelds in each transverse slice
and presented as the mean number of blood vessels per unit
area (preset at mm2).Detection and quantiﬁcation of apoptotic cells
Apoptotic cells were detected using tunnel staining (Roche,
Germany), performed according to the manufacturer’s
VEGF F 5′ GTTCGAGGAAAGGGAAAGGGTC 3′
R 5′ GCGAGTCTGTGTTTTTGCAGGA 3′
Ang-2 F 5′GATGGCAGCGTTGATTTTCA 3′
R 5′ACATGCATCAAACCACTGGC 3′
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Figure 2. FISH was performed on tissue slices selected at random from each group. No Sry-positive cells were present in the control group
( tecte
( 1, × 4
× lso po
I
s
R
R
m
F
r
d
d
d
w
s
v
7
t
t
t
f
7
E
t
T
t
t
w
a
c
(
t
f
t
0
o
f
g
t
C
A
d
f
s
a
e
g
E
t
s
a
a
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D, × 200) and the EPC group (E, × 400). Some Sry-positive cells (D
400). Some Sry-positive cells (E1, × 400) in the EPC group were a
nc. Chicago, USA). A P-value less than 0.05 was considered
tatistically signiﬁcant.
esults
at model of isoproterenol-induced
yocardial injury
ifty-ﬁve of 70 female rats survived ISO injection. Five
ats were excluded from the study because of insufﬁcient
ecrease in cardiac performance. Increased LVEDD with
ecreased ejection fraction and fractional shortening was
emonstrated by echocardiography in 50 female rats, four
eeks after ISO injection (LVEDD, pre 0.45± 0.05 cm ver-
us post 0.67± 0.04 cm; ejection fraction, pre 77.47± 1.97%
ersus post 56.16± 4.23%; fractional shortening, pre
3.20± 6.30% versus post 36.69± 2.23%; P < 0.05, respec-
ively). These 50 rats were divided randomly into the ﬁve
reatment groups (10 per group). After stem-cell transplan-
ation, the ﬁnal numbers in each treatment group were as
ollows: control, 6; EGM-2, 7; MSC, 7; EPC, 8; and EPC/MSC,
.
ngraftment and differentiation of
ransplanted cellswelve weeks after stem-cell transplantation, FISH revealed
hat Sry-positive cells were not present in heart tissue in
he control group (Fig. 2A) or the EGM-2 group (Fig. 2B), but
ere present in heart tissue in the EPC/MSC group (Fig. 2C)
nd the MSC group (Fig. 2D). In the EPC group, Sry-positive
w
a
n
t
ad in cardiac tissue in the EPC/MSC group (C, × 400), the MSC group
00) in the MSC group were also positive for cardiac troponin T (D2
sitive for vWF (E2, × 400).
ells were found in blood vessels (Fig. 2E). Sry-positive cells
Fig. 2D1) from the MSC group were shown to express cardiac
roponin T (Fig. 2D2). Similarly, Sry-positive cells (Fig. 2E1)
rom the EPC group were shown to express vWF (Fig. 2E2).
Real time RT-PCR analysis showed that expression of
he Sry gene was higher in the EPC/MSC group (CT,
.32± 0.04%) than in the EPC group (0.21± 0.07%; P < 0.05)
r the MSC group (0.19± 0.06%; P < 0.05). There was no dif-
erence in Sry gene expression between the EPC and MSC
roups (P > 0.05). Sry gene expression was not detectable in
he EGM-2 and control groups.
ardiac function and haemodynamics
s summarized in Table 2, the EGM-2 and control groups
id not show a signiﬁcant improvement in cardiac per-
ormance, 12 weeks after cell transplantation. However,
imilar degrees of improvement were seen in the MSC
nd EPC groups, with regard to fractional shortening,
jection fraction and LVEDD (P < 0.05, respectively). The
reatest improvement in cardiac function was seen in the
PC/MSC group (P < 0.05) although the differences between
he EPC/MSC group and the MSC and EPC groups were not
tatistically different in terms of LVEDD (P > 0.05). Intrac-
rdiac pressure recordings showed that the maximum rise
nd fall in left ventricular pressure (±dP/dtmax) and LVEDP
mproved signiﬁcantly in the MSC and EPC groups compared
ith the control and EGM-2 groups (P < 0.05, respectively),
nd that the difference in improvement was even more pro-
ounced in the EPC/MSC group (P < 0.05, respectively); these
hree variables were not signiﬁcantly different in the EPC
nd MSC groups (P > 0.05, respectively).
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Table 2 Cardiac function and haemodynamic proﬁles.
Group Ejection
fraction (%)
Fractional
shortening (%)
LVEDD (cm) LVEDP (mmHg) +dp/dt
(mmHg/s)
−dp/dt
(mmHg/s)
Control 55.68 ± 3.34 36.82 ± 1.89 0.69 ± 0.06 22.11 ± 5.70 4380.41 ± 634.96 5189.02 ± 504.59
EGM-2 55.04 ± 3.53 35.45 ± 1.44 0.69 ± 0.09 23.68 ± 4.37 4191.31 ± 568.30 5003.07 ± 585.37
MSC 62.85 ± 4.84* 42.36 ± 2.91* 0.62 ± 0.04* 18.59 ± 2.16* 4470.55 ± 484.53* 4605.51 ± 473.30*
EPC 63.43 ± 4.49* 43.86 ± 2.54* 0.61 ± 0.05* 18.98 ± 2.38* 4573.71 ± 443.45* 4546.51 ± 360.38*
EPC/MSC 68.23 ± 2.69† 47.09 ± 2.17† 0.60 ± 0.05* 14.76 ± 2.26† 4996.74 ± 523.16† 4233.74 ± 437.28†
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Capillary density and regional myocardial
blood ﬂow
Representative images of myocardial capillary density,
identiﬁed by vWF-targeted immunostaining, are shown in
Fig. 3A—E. The increase in total capillary density was signif-
icantly greater in the MSC group (33.67± 4.09 per millimetre
square) than in the EGM-2 (26.00± 4.00 per millimetre
square; P < 0.05) or control groups (24.33± 6.77 per millime-
tre square; P < 0.05), but was even more notable in the EPC
group (38.33± 6.11 per millimetre square; P < 0.05 versus
the MSC group). When MSCs and EPCs were combined, the
increase in total capillary density (42.37± 9.26 per millime-
tre square) was not signiﬁcantly greater than that seen in
the EPC group (P > 0.05).
In line with capillary density data, the increase in aver-
age RMBF was signiﬁcantly greater in the EPC group (6.66±
0.46mL/min) than in the MSC group (3.61± 0.59mL/min;
P < 0.05), the EGM-2 group (2.35± 0.61mL/min; P < 0.05)
and the control group (2.47± 0.38mL/min; P < 0.05). The
combination of MSCs and EPCs induced a signiﬁcantly greater
increase in average RMBF (7.14± 0.89mL/min) than MSCs
alone (P < 0.05), but the increase was not signiﬁcantly
greater than that induced by EPCs alone (P > 0.05).
Myocardial ﬁbrosis
Masson’s trichrome staining showed patchy areas of ﬁbro-
sis in the heart tissue in all groups (Fig. 3F—J). After cell
transplantation, there was less collagen deposition in heart
tissue in the MSC group (Fig. 3H, 31.81± 4.54%) and the
EPC group (Fig. 3I, 30.28± 4.34%) than in the EGM-2 group
(Fig. 3G, 36.18± 3.85%; P < 0.05) and the control group
(Fig. 3F, 34.52± 5.19%; P < 0.05). No signiﬁcant difference
was detected between the EGM-2 and control groups, or
between the EPC and MSC groups (P > 0.05, respectively).
There was signiﬁcantly less ﬁbrosis in the EPC/MSC group
(Fig. 3J, 25.59± 6.86%; P < 0.05) than in the other four
groups.
Apoptotic indexAs shown in Fig. 3K—O, each of the three groups that
received stem-cell therapy had a signiﬁcantly lower apop-
totic index (EPC/MSC, 11.35± 1.70%; MSC, 21.12± 2.65%;
EPC, 20.80± 2.58%) than the EGM-2 group (31.24± 10.52%;
P < 0.05) and the control group (33.06± 8.01%; P < 0.05). The
e
c
a
e
cgroup.
poptotic index in the EPC/MSC group was signiﬁcantly lower
han that in the MSC and EPC groups (P < 0.05, respectively),
ut there was no signiﬁcant difference between the EPC
nd MSC groups, or between the EGM-2 and control groups
P > 0.05, respectively).
ngiogenic growth factor protein and mRNA
xpression
ata on levels of angiogenic growth factor protein and
RNA expression are summarized in Table 3. VEGF, b-FGF
nd Ang-2 protein levels were slightly increased in the MSC
roup compared with the EGM-2 and control groups (P < 0.05,
espectively). Both the EPC/MSC and the EPC groups had a
igniﬁcantly greater increase in the level of protein expres-
ion than the MSC group (P < 0.05). The EPC group had a
igniﬁcantly higher level of b-FGF protein expression than
he EPC/MSC group (P < 0.05).
Real-time RT-PCR analysis of the targeted genes for
hese proteins revealed a higher level of mRNA expression
n the MSC group than in the EGM-2 and control groups
P < 0.05, respectively), and mRNA expression levels were
ven greater in the EPC/MSC and EPC groups. However, the
evel of b-FGF mRNA expression in the EPC group did not dif-
er from that in the EPC/MSC group (P > 0.05, respectively).
iscussion
sing a rat model of injured myocardium induced by ISO
njection, we have shown that the combined transplanta-
ion of EPCs and MSCs, compared with transplantation of
PCs or MSCs alone, results in a greater improvement in
ardiac function in terms of increase in ejection fraction
nd fractional shortening, decrease in LVEDP and changes in
aximum left ventricular pressure.
In investigating the underlying mechanisms, we
bserved: the presence of Sry-positive cells in heart
issue, indicating that the transplanted cells had either
ifferentiated or integrated into heart tissue; upregulation
f expression of angiogenic growth factors, including VEGF,
-FGF and Ang-2; an association between the increased
xpression of these angiogenic factors and an increase in
apillary density, which in turn led to an improvement in
verage RMBF; a potential reversal process, as histological
xamination revealed less ﬁbrosis and fewer apoptotic
ells.
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pigure 3. Immunostaining against vWF to identify capillaries (A
ollagen stained in green, myocardium stained in red) and Tunnel s
nd EPC/MSC groups, respectively.
The pathological process of ISO-induced myocardial dam-
ge is characterized by patchy areas of myocardial infarction
ith well-maintained coronary vasculature. This model has
lso been shown to exhibit dose-dependent progression
f postmyocardial infarction remodelling [8]. Although the
nderlying mechanism is not fully understood, there are
ertain similarities with traditional myocardial infarction
ttributable to ischaemic coronary disease, as oxidative
tress is the main trigger for cardiac injury [7]. Using this
SO-induced myocardial injury model for the ﬁrst time, we
ere able to demonstrate that the combination of EPCs
nd MSCs may induce neovascularization and hence aug-
ent cardiac performance. Our reasons for undertaking
ombined transplantation of EPCs and MSCs were based
n the different biological properties of these stem cells.
d
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n
w
w
Table 3 Angiogenic growth factor protein and mRNA expressi
Group VEGF
protein (pg/mg) mRNA (%) protein (pg/m
Control 110.03 ± 4.31 2.91 ± 1.53 426.87 ± 25.4
EGM-2 121.38 ± 2.93 3.21 ± 1.10 415.30 ± 37.6
MSC 134.48 ± 4.88* 4.93 ± 2.10* 545.50 ± 65.7
EPC 154.25 ± 32.91† 7.97 ± 2.11† 972.41 ± 204.
EPC/MSC 185.75 ± 13.20‡ 27.05 ± 1.84‡ 732.85 ± 51.2
*P < 0.05 vs EGM-2 group; †P < 0.05 vs EGM-2 group and MSC group; ‡P <Masson’s trichrome staining to detect myocardial ﬁbrosis (F—J;
g to detect apoptotic cells (K—O) in the control, EGM-2, MSC, EPC
mproved myocardial contractility has been observed in
clinical trial where both EPCs and MSCs were used
or transcoronary transplantation in patients with myocar-
ial infarction [11]. The mechanism by which combined
ransplantation of EPCs and MSCs improves cardiac func-
ion signiﬁcantly is not fully understood, but we have
cquired a number of pieces of evidence that support this
ffect.
Firstly, we found evidence of transplanted cells incor-
orated into cardiac tissue. Sry-positive cells may have
ifferentiated into cardiac tissue cells, as they exhibited
ositive immunostaining for troponin T, although we can-
ot exclude the possibility that these MSCs had merged
ith pre-existing cardiac tissue cells. The same phenomenon
as observed for EPCs implanted into cardiac tissue, as
on.
b-FGF Ang-2
g) mRNA (%) protein (ng/mg) mRNA (%)
6 11.86 ± 3.37 1.18 ± 0.24 9.93 ± 6.79
6 12.46 ± 2.14 1.01 ± 0.10 9.81 ± 4.83
6* 17.81 ± 5.65* 1.31 ± 0.10* 12.84 ± 4.10*
21† 38.66 ± 14.50† 1.46 ± 0.05† 18.40 ± 6.97†
5‡ 36.43 ± 12.68† 1.73 ± 0.15‡ 32.01 ± 13.80‡
0.05 vs EGM-2 group, MSC group and EPC group.
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[Combined transplantation of endothelial progenitor cells an
Sry-positive cells detected by FISH were also positive for
immunoﬂuorescence staining against vWF in the EPC group.
In addition, the levels of angiogenic growth factor protein
and mRNA expression were higher in the EPC and EPC/MSC
groups than in MSC group. The factors in question (VEGF,
b-FGF and Ang-2) have been shown to augment neovascular-
ization and hence increase capillary density [12]. b-FGF is a
powerful mitogen that stimulates the migration and prolifer-
ation of various vascular cell types, including smooth-muscle
cells, endothelial cells and ﬁbroblasts [13]. Ang-2 can stim-
ulate the degradation of the base membrane by proteases
secreted by activated endothelial cells, which aids migra-
tion, proliferation, and the formation of solid endothelial
cell sprouts into the stromal space [14]. We were surprised
to observe a higher level of b-FGF protein expression in the
EPC group than in the EPC/MSC group, but a similar level
of b-FGF mRNA expression in these two groups. This dif-
ference in post-translational regulation might be due to the
interaction between EPCs and MSCs; the detailed underlying
mechanism requires further investigation.
The beneﬁcial effect of the increase in angiogenic fac-
tors was evidenced by the higher Sry gene expression levels
detected by real time RT-PCR, indicating a synergetic effect
of the combination therapy in enhancing either engraftment
rate or possibly proliferative activity.
Finally, we observed the lowest level of ﬁbrosis depo-
sition in cardiac tissue in the EPC/MSC group, indicating a
potential reversal of cardiomyopathy. We did not investi-
gate the mechanism underlying this effect but propose that
it may have been associated with the paracrine effects of
the angiogenic factors secreted by transplanted cells and
the lower numbers of apoptotic cells.
Recently, Suuronen et al. reported that the transplanta-
tion of EPCs resulted in better cardiac function, increased
arteriole density and less myocardial ﬁbrosis in a rat model
of myocardial infarction than the transplantation of MSCs,
or EPCs plus MSCs [15]. These results are strikingly different
from our data, and can be attributed to a number of factors:
a much shorter observation period post-transplantation; the
use of far fewer EPCs and MSCs; a relatively superior baseline
cardiac performance before cell transplantation (relatively
smaller decrease in cardiac function compared with baseline
before coronary ligation); and the use of a different animal
model, involving different pathological processes.
Given the immunogenic properties of EPCs, it is advisable
that the immunosuppressant cyclosporine A is adminis-
tered. However, it is still uncertain whether cyclosporine
A enhances the engraftment rate of cell therapy [16], and
one report has shown that it can even suppress the differ-
entiation process [17].
In conclusion, our study has shown for the ﬁrst time
that the intramyocardial infusion of culture-expanded EPCs
together with MSCs may represent a novel and more efﬁ-
cient therapeutic strategy for the treatment of ISO-induced
cardiomyopathy.Limitations of the study
Our study was limited by the small sample size. In addi-
tion, we should have attempted to use BMNCs as control
cells. Also, we were unable to label all the stem cells before
[senchymal stem cells 341
ransplantation, to enable us to identify the cells in vivo;
his made the evaluation of engrafted stem cells more difﬁ-
ult. The ISO-induced cardiac injury model also has its own
rawback, characterized by patchy areas of necrosis rather
han a ﬁxed risk area, which can make results difﬁcult to
nterpret. Nevertheless, the data showed that the combined
ransplantation of EPCs and MSCs into a rat model of isopro-
erenol (ISO)-induced injured myocardium improved cardiac
unction after 12 weeks. We excluded all rats with a drop in
yocardial performance of less or equal to 20% to minimize
he variability inherent in this animal model. Further study
s warranted to elucidate detailed underlying mechanisms,
nd an extended observation period is required to validate
ong-term outcome.
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